Clinical trial
A Randomized, Open-label, Uncontrolled Study of Tislelizumab in Combination With Chemotherapy or Radiation Therapy for Neoadjuvant Therapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (TINES)
NCT05603065 is registered in ClinicalTrials.gov with First Affiliated Hospital Xi'an Jiaotong University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label, Uncontrolled Study of Tislelizumab in Combination With Chemotherapy or Radiation Therapy for Neoadjuvant Therapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (TINES)
- Lead sponsor
- First Affiliated Hospital Xi'an Jiaotong University
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- October 10, 2022
- Completion date
- October 31, 2024
- Enrollment
- 32 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.